High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention (Q39612863)

13 September 2017

title

High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention (English)

1 reference

13 September 2017

0 references

0 references

Xavier Carbonell-Estrany

4

object named as

X Carbonell-Estrany

1 reference

13 September 2017

P Manzoni

1

1 reference

13 September 2017

B Paes

2

1 reference

13 September 2017

B Resch

3

1 reference

13 September 2017

L Bont

5

1 reference

13 September 2017

language of work or name

1 reference

1 May 2012

1 reference

13 September 2017

published in

Early Human Development

1 reference

13 September 2017

volume

88 Suppl 2

1 reference

13 September 2017

page(s)

S34-41

1 reference

Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

The burden of respiratory syncytial virus infection in young children

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Viral respiratory infections in children with technology dependence and neuromuscular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial viral infection in children with compromised immune function

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial virus infection in human immunodeficiency virus-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Fatal respiratory syncytial virus pneumonia as the presenting feature of severe combined immunodeficiency disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Mortality associated with influenza and respiratory syncytial virus in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Trends in deaths from respiratory illness in children in England and Wales from 1968 to 2000

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

1 reference

7 January 2021

Virological analysis in the diagnosis of sudden children death: a medico-legal approach.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Detection of RNA viruses in sudden infant death (SID).

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

1 reference

7 January 2021

Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory morbidity in adulthood after respiratory syncytial virus hospitalization in infancy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Impact of wheezing after respiratory syncytial virus infection on health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial viral infection in infants with congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks' gestational age.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

[The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain]

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Risk factors for respiratory syncytial virus hospitalisation in children with heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Severe respiratory syncytial virus infection in term infants with genetic or other underlying disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Down syndrome and respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Severe viral respiratory infections in infants with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Risk of respiratory syncytial virus in survivors with severe congenital diaphragmatic hernia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Airway anomalies in children with Down syndrome: endoscopic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Down syndrome: Patterns of disturbed lung growth

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Clinical characteristics and follow up of Down syndrome infants without congenital heart disease who presented with persistent pulmonary hypertension of newborn

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Intrinsic defect of the immune system in children with Down syndrome: a review.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial virus infection in a murine model of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial virus infection facilitates acute colonization of Pseudomonas aeruginosa in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Decreased bacterial clearance from the lungs of mice following primary respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

A survey of palivizumab for infants with cystic fibrosis in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

North American synagis prophylaxis survey

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Congenital diaphragmatic hernia and associated cardiovascular malformations: type, frequency, and impact on management

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

The long-term follow-up of patients with a congenital diaphragmatic hernia: a broad spectrum of morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Pulmonary morbidity in 100 survivors of congenital diaphragmatic hernia monitored in a multidisciplinary clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Lung volumes, ventricular function and pulmonary arterial flow in children operated on for left-sided congenital diaphragmatic hernia: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Pulmonary function and exercise capacity in survivors of congenital diaphragmatic hernia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Long-term follow-up of patients with high-risk congenital diaphragmatic hernia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Long-term follow-up of children with diaphragmatic hernia.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Survival of severe congenital diaphragmatic hernia has morbid consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Late-onset right-sided diaphragmatic hernia in neonates - case report and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

An overview of pediatric dysphagia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Deep laryngeal penetration as a predictor of aspiration

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Gastroesophageal reflux in infants with wheezing

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Managing gastro-oesophageal reflux in infancy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Previously healthy infants may have increased risk of aspiration during respiratory syncytial viral bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Increased laryngeal lavage lipid-laden macrophage index during acute bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Aspiration: a factor in rapidly deteriorating bronchiolitis in previously healthy infants?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Recurrent severe lower respiratory tract infections in a child with abnormal tracheal morphology

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Local immune response to respiratory syncytial virus infection is diminished in senescence-accelerated mice

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Community respiratory viruses in individuals with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

An outbreak of respiratory syncytial virus in a bone marrow transplant center

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory virus infections in bone marrow transplant recipients: the European perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0378-3782%2812%2970012-9

7 January 2021

10.1016/S0378-3782(12)70012-9

Identifiers

DOI

1 reference

13 September 2017

1 reference